Vendors to focus on the development of combination therapies for different types of leukemia
Technavio, a company that develops over 2000 pieces of research every year and covers more than 500 technologies across 80 countries, has announced the top five leading vendors for the global leukemia therapeutics market in their latest research report. This report also lists 62 other prominent vendors who are expected to contribute to this market’s growth between 2016-2020.
To identify the top vendors, Technavio’s market research analysts have taken into account the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of different types of leukemia.
This Technavio report, under the oncology vertical, is based on the synthesis, analysis, and interpretation of information about the global leukemia therapeutics market collected from specialized sources. The analysts have derived insights using a mix of primary and secondary research with an aim to provide a holistic picture of the market.
Click here to request a free sample of this report
Competitive vendor landscape
The global market for leukemia therapeutics is characterized by the presence of many established vendors. The market has a high potential for growth owing to the rapidly rising demand for leukemia therapeutics in the market. The rise in demand is also expected to prompt vendors to make increased investments in R&D activities. Most vendors in the market emphasize on the manufacture and marketing of drugs that can effectively treat leukemia apart from having a high efficacy and safety profile. Such an approach also enables the vendors to gain market shares and strengthen their foothold in the competitive market for leukemia therapeutics.
“Vendors are currently focusing on the development of combination therapies for the treatment of leukemia. The majority of such combination therapies are available in the form of combination chemotherapy drugs. Some of the approved combinations include chlorambucil with prednisone, and cyclophosphamide with vincristine and prednisone for the treatment of CLL; a combination of cytarabine, daunorubicin, and etoposide for the treatment of AML; and a combination of hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone for the treatment of ALL. The development of such combination therapies is anticipated to increase the effectiveness in treating the condition, resulting in increased patient compliance towards the use of these drugs,” says Barath Palada, a lead analyst at Technavio for research on oncology.
Top five vendors in the leukemia therapeutics market space
F. Hoffmann-La Roche
F. Hoffmann-La Roche operates through a pharmaceutical as well as diagnostics business line. The company generated revenue of more than $50 billion in FY2015. F. Hoffmann-La Roche caters to the demand of hospitals and commercial labs, ICUs, individuals, physicians, pharmacies, homes, and blood banks. The company’s primary focus is on the development of new combination products for the treatment of different types of leukemia. It formed a partnership with AbbVie for the development of the recently launched drug, Venclexta, which is expected to help in the growth of the leukemia therapeutics market.
Key products: Rituxan/MabThera, GAZYVA, and VENCLEXTA
Novartis
The company focuses on the research, manufacture, and marketing of healthcare products across the globe. In FY2015, the company generated revenue of more than $49 billion and spent almost $9 billion on R&D. Retail and wholesale customers, government agencies, insurance companies, and managed healthcare organizations constitute Novartis’ consumer base. In April 2014, the company acquired GlaxoSmithKline’s oncology products including ARZERRA, for around $15 billion. Novartis also collaborated with Genmab for the development of ARZERRA.
Key products: Tasigna, Gleevec/Glivec, ARZERRA, and ARRANON.
Bristol-Myers Squibb
Bristol-Myers Squibb’s primary focus areas are the development, manufacture, marketing and sales of pharmaceutical and nutritional products. The company’s product offerings include medicines for diseases such as cancer, cardiovascular diseases, hepatitis B and hepatitis C, HIV, and rheumatoid arthritis. For FY2015, the company generated revenue of almost $17 billion.
Key products: SPRYCEL, Cytoxan, and Vumon.
AbbVie
AbbVie develops and markets advanced therapies for the treatment of diseases such as chronic autoimmune diseases, including psoriasis, rheumatoid arthritis, and Crohn’s disease, HIV, hepatitis C, thyroid disease, endometriosis, and Parkinson’s disease. In FY2015, the company reported revenue of almost $23 billion.
Key products: IMBRUVICA and VENCLEXTA.
Teva Pharmaceuticals
Teva Pharmaceuticals offers generic medicines and specialty pharmaceutical products. Its products are sold in over 100 countries worldwide and the company operates across 60 countries. In FY2015, the company reported revenue of around $20 billion and spent almost $2 billion on R&D. Patients, physicians, wholesalers, pharmacies, and payors constitute Teva Pharmaceuticals’ targeted customers.
Key products: TREANDA and Bendeka.
Other prominent vendors in this market include Altor BioScience, Ambit BioSciences, Amgen, Ariad Pharmaceuticals, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer HealthCare, Bellicum Pharmaceuticals, Biogen, Boehringer Ingelheim, BioLineRx, Boston Biomedical, Celator Pharmaceuticals, Celgene Corporation, CTI Biopharma, Chroma Therapeutics, Chugai Pharmaceutical, Cyclacel Pharmaceuticals, Daiichi Sankyo, Eisai, Emergent BioSolutions, Erytech Pharma, Fate Therapeutics, Genzyme Corp, Gilead Sciences, GlaxoSmithKline, iDD biotech, Immune Pharmaceuticals, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Ligand Pharmaceuticals, Meda, MedImmune, Merck, Midas Pharmaceuticals, Molecular Templates, MorphoSys, Nippon Shinyaku, Novo Nordisk, Onconova Therapeutics, Ono Pharmaceuticals, Orphan Europe, Otsuka, Pfizer, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals, Stemline Therapeutics, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, Tolero Pharmaceuticals, XEME Biopharma, Xencor, and ZIOPHARM Oncology.
A more detailed analysis is available in the Technavio report, Global Leukemia Therapeutics Market 2016-2020. Technavio also customizes reports by other regions and specific segments upon request.
To read more press releases- click here.
Browse related reports:
- Global Chronic Lymphocytic Leukemia Therapeutics Market 2016-2020
- Global Acute Lymphocytic Leukemia Market 2015-2019
- Global Cancer Diagnostic Devices Market 2016-2020
- Global Cancer Pain Therapeutics Market 2015-2019
- Global Cancer Immunotherapies Market 2016-2020
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
